Chimeric Peptide Vaccine Aims to Use Memory Imprint to Yield a Strong and
Highly Specific Immune Response
NEW YORK, Aug. 20 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, announced today that Dr. Rachel Eren, Vice President Research, will present new data regarding the Company's RECALL-VAX(TM) chimeric peptide vaccine technology at the 13th International Congress of Immunology on Thursday, August 23, 2007 in Rio de Janeiro, Brazil. Mice immunized with RECALL-VAX(TM) constructs mounted a robust and highly specific immune response against beta-amyloid. The data demonstrate for the first time that a "free-end specific" polyclonal response to beta-amyloid can be achieved, potentially overcoming an important safety concern for active immunization of Alzheimer's disease patients.
"We are pleased with our scientists' progress in establishing important proof of principle for this novel and proprietary vaccine technology, which is designed to make active immunization safe and practical for treating Alzheimer's patients," commented Dr. Daniel Chain, Intellect's Chairman and CEO. He added: "We believe that RECALL-VAX(TM) could potentially be used prophylactically to prevent or delay the onset of Alzheimer's disease in elderly people."
"There are multiple challenges in developing a means to safely immunize
elderly individuals and avoid the failures encountered in previous clinical
trials sponsored by major pharmaceutical companies," commented Professor
Benjamin Chain at the Department of Immunology and Molecular Pathology,
Windeyer Institute of Medical Sciences, University College London.
Professor Chain added: "The major challenges are the need to: (i) mount a
robust immune response when the immune system has become senescent as
|SOURCE Intellect Neurosciences, Inc.|
Copyright©2007 PR Newswire.